Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Cochrane Evaluates Partial vs Radical Nephrectomy
Cochrane; 2017 May 9; Kunath, Schmidt, et al
Partial nephrectomy may be linked with a decreased time-to-death of any cause, according to a recent Cochrane review of a randomized trial involving 541 individuals. It appears to result in little to no difference in surgery-related mortality, cancer-specific survival, and time-to-recurrence.
The study randomly assigned participants with localized kidney tumors that were thought to be cancerous to either partial or radical nephrectomy. Investigators followed them for an average of just over 9 years. Among the results:
- Patients who had only the tumor taken were more likely to die from any cause than those who had the tumor and whole kidney removed.
- There was little to no difference in the time until the tumor came back or in the risk of serious complications resulting in death.
- There was no evidence between the 2 groups regarding the need for hemodialysis.
- Quality of life was also similar in the 2 contingents.
Kunath F, Schmidt S, Krabbe L, et al. Partial nephrectomy versus radical nephrectomy for clinical localised renal masses. Cochrane Database of Systematic Reviews. 2017, Issue 5. Art. No.: CD012045. doi:10.1002/14651858.CD012045.pub2.
This Week's Must Reads
Must Reads in Clinical Guidelines
ASCO Guideline on Alcohol Consumption and Cancer, J Clin Oncol; 2018 Jan; LoConte, Brewster, et al
Guideline on Platelet Transfusion in Ca Patients, J Clin Oncol; ePub 2017 Nov 28; Schiffer, et al
Guideline on Preventing VTE in Pediatric Cancer, J Thromb Haemost; ePub 2017 Nov 27; Tullius, et al
ASCO Updates Guideline on Role of BMAs in BC, J Clin Oncol; ePub 2017 Oct 16; Van Poznak, et al
Cochrane on Heparin Impact in People with Cancer , Cochrane; 2017 Sep 11; Akl, Kahale, et al